Fit for the Eye: Aptamers in Ocular Disorders

Nucleic Acid Therapeutics

Volumn 26, Issue 3, 2016, Pages 127-146

  Drolet, Daniel W ^a   Green, Louis S ^a   Gold, Larry ^a   Janjic, Nebojsa ^a  

^a SomaLogic Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; AVACINCAPTAD PEGOL; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE 19; PEGAPTANIB; PEGPLERANIB; PLATELET DERIVED GROWTH FACTOR B; STROMELYSIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN 206; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; LIGAND;

AGE RELATED MACULAR DEGENERATION; ALTERNATIVE RNA SPLICING; CELL MIGRATION; CELL PROLIFERATION; COMPLEMENT SYSTEM; DNA SYNTHESIS; EXON; EYE DISEASE; GENETIC ASSOCIATION; HUMAN; IN VITRO SELECTION; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL FACTOR; SUSTAINED RELEASE FORMULATION; VEGF SIGNALING; GENETICS; OPHTHALMOLOGY; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; TRENDS;

APTAMERS, NUCLEOTIDE; EYE DISEASES; HUMANS; LIGANDS; OPHTHALMOLOGY; SELEX APTAMER TECHNIQUE;

EID: 84975053283     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2015.0573     Document Type: Review

References (189)

1. Tuerk C and L Gold. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
2. Ellington AD and JW Szostak. (1990). In vitro selection of RNAmolecules that bind specific ligands.Nature 346:818-822.
3. Pieken W, D Olsen, F Benseler, H Aurup and F Eckstein. (1991). Kinetic characterization of ribonuclease-resistant 2-modified hammerhead ribozymes. Science 253:314-317.
4. Fitzwater T and B Polisky. (1996). A SELEX primer. Methods in Enzymology 267:275-301.
5. Jellinek D, LS Green, C Bell, CK Lynott, N Gill, C Vargeese, G Kirschenheuter, DP McGee, P Abesinghe, et al. (1995). Potent 2-Amino-2-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34:11363-11372.
6. Lin Y, Q Qiu, SC Gill and SD Jayasena. (1994). Modified RNA sequence pools for in vitro selection. Nucleic Acids Res 22:5229-5234.
7. Pagratis NC, C Bell, Y-F Chang, S Jennings, T Fitzwater, D Jellinek and C Dang. (1997). Potent 2-Amino-, and 2-fluoro-2-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat Biotechnol 15:68-73.
8. Folkman J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-30.
9. Jellinek D, CK Lynott, DB Rifkin and N Janjic. (1993). High-Affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proc Natl Acad Sci U S A 90:11227-11231.
10. Jellinek D, LS Green, C Bell and N Janjic. (1994). Inhibition of receptor binding by high-Affinity RNA ligands to vascular endothelial growth factor. Biochemistry 33:10450-10456.
11. Dvorak HF, NS Orenstein, AC Carvalho, WH Churchill, AM Dvorak, SJ Galli, J Feder, AM Bitzer, J Rypysc, et al. (1979). Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumorsecreted products. J Immunol 122:166-174.
12. Senger D, S Galli, A Dvorak, C Perruzzi, V Harvey and HF Dvorak. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
13. Leung D, G Cachianes, W Kuang, D Goeddel and N Ferrara. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309.
14. Keck P, SHauser, GKrivi, KSanzo, TWarren, J Feder andDT Connolly. (1989).Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309-1312.
15. Gospodarowicz D, JA Abraham and J Schilling. (1989). Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci U S A 86:7311-7315.
16. Tischer E, D Gospodarowicz, R Mitchell, M Silva, J Schilling, K Lau, T Crisp, JC Fiddes and JA Abraham. (1989). Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 165:1198-1206.
17. Conn G, DD Soderman, MT Schaeffer, M Wile, VB Hatcher and KA Thomas. (1990). Purification of a glycoprotein vascular endothelial cell mitogen from a rat gliomaderived cell line. Proc Natl Acad Sci U S A 87:1323-1327.
18. Berse B, LF Brown, L Van de Water, HF Dvorak and DR Senger. (1992). Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211-220.
19. Dvorak HF, LF Brown, M Detmar and AM Dvorak. (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039.
20. Shweiki D, A Itin, D Soffer and E Keshet. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845.
21. Kim KJ, B Li, J Winer, M Armanini, N Gillett, HS Phillips and N Ferrara. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844.
22. Klagsbrun M and S Soker. (1993). VEGF/VPF: The angiogenesis factor found? Curr Biol 3:699-702.
23. Pepper MS, N Ferrara, L Orci and R Montesano. (1991). Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 181:902-906.
24. Unemori EN, N Ferrara, EA Bauer and EP Amento. (1992). Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 153:557-562.
25. de Vries C, J Escobedo, HUeno, KHouck, NFerrara and LT Williams. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991.
26. Terman BI, M Dougher-Vermazen, ME Carrion, D Dimitrov, DC Armellino, D Gospodarowicz and P Böhlen. (1992). Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187:1579-1586.
27. Millauer B. (1993). High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846.
28. Ferrara N. (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611.
29. Houck KA, N Ferrara, J Winer, G Cachianes, B Li and DW Leung. (1991). The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814.
30. Tischer E, R Mitchell, T Hartman, M Silva, D Gospodarowicz, JC Fiddes and JA Abraham. (1991). The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954.
31. Carmeliet P, YS Ng, D Nuyens, G Theilmeier, K Brusselmans, I Cornelissen, E Ehler, VV Kakkar, I Stalmans, et al. (1999). Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5:495-502.
32. Gitay-Goren H, T Cohen, S Tessler, S Soker, S Gengrinovitch, P Rockwell, M Klagsbrun, BZ Levi and G Neufeld. (1996). Selective binding of VEGF to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J Biol Chem 271:5519-5523.
33. Keyt BA, LT Berleau, HV Nguyen, H Chen, H Heinsohn, R Vandlen and N Ferrara. (1996). The carboxyl-Terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271:7788-7795.
34. Plouet J, F Moro, S Bertagnolli, N Coldeboeuf, H Mazarguil, S Clamens and F Bayard. (1997). Extracellular cleavage of the vascular endothelial growth factor 189-Amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 272:13390-13396.
35. Lee S. (2005). Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681-691.
36. Ferrara N, L Damico, N Shams, H Lowman and R Kim. (2006). Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859-870.
37. Fong G-H, J Rossant, M Gertsenstein and ML Breitman. (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70.
38. Hiratsuka S, O Minowa, J Kuno, T Noda and M Shibuya. (1998). Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A 95:9349-9354.
39. Kendall RL and KA Thomas. (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 90:10705-10709.
40. Shalaby F, J Rossant, TP Yamaguchi, M Gertsenstein, XF Wu, ML Breitman and AC Schuh. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66.
41. Eichmann A, C Corbel, V Nataf, P Vaigot, C Breant and NM Le Douarin. (1997). Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc Natl Acad Sci U S A 94: 5141-5146.
42. Ferrara N, K Carver-Moore, H Chen, M Dowd, L Lu, KS OShea, L Powell-Braxton, KJ Hillan and MW Moore. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442.
43. Carmeliet P, V Ferreira, G Breier, S Pollefeyt, L Kieckens, M Gertsenstein, M Fahrig, A Vandenhoeck, K Harpal, et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439.
44. Storkebaum E and P Carmeliet. (2004). VEGF: A critical player in neurodegeneration. J Clin Invest 113:14-18.
45. Oosthuyse B, L Moons, E Storkebaum, H Beck, D Nuyens, K Brusselmans, Van J Dorpe, P Hellings, M Gorselink, et al. (2001). Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28:131-138.
46. Lambrechts D, E Storkebaum, M Morimoto, J Del-Favero, F Desmet, SL Marklund, S Wyns, V Thijs, J Andersson, et al. (2003). VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34:383-394.
47. Nishijima K, Y-SNg, L Zhong, J Bradley, WSchubert, NJo, J Akita, SJ Samuelsson, GS Robinson, et al. (2007). Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53-67.
48. Saint-Geniez M, T Kurihara, E Sekiyama, AE Maldonado and PA DAmore. (2009). An essential role for RPEderived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A 106:18751-18756.
49. Highlights of Prescribing Information AVASTIN- (Bevacizumab) Solution for Intravenous Infusion. (2015). Retrieved September 24, 2015 fromDrugs@FDAweb sitewww .accessdata.fda.gov/drugsatfda-docs/label/2015/125085s308 lbl.pdf05/2015
50. Aiello LP, RL Avery, PG Arrigg, BA Keyt, HD Jampel, ST Shah, LR Pasquale, H Thieme, MA Iwamoto, et al. (1994). Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487.
51. Adamis AP, JW Miller, M-T Bernal, DJ DAmico, J Folkman, TK Yeo and KT Yeo. (1994). Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445-450.
52. Miller JW, AP Adamis, DT Shima, PA DAmore, RS Moulton, MS OReilly, J Folkman, HF Dvorak, LF Brown, et al. (1994). Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145:574-584.
53. Blaauwgeers HG, GM Holtkamp, H Rutten, AN Witmer, P Koolwijk, TA Partanen, K Alitalo, ME Kroon, A Kijlstra, et al. (1999). Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Am J Pathol 155:421-428.
54. Michelson IC. (1948). The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. T Ophthal Soc UK 68:137-180.
55. Lee SW and BA Sullenger. (1996). Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. J Exp Med 184:315-324.
56. Lee SW and BA Sullenger. (1997). Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nat Biotechnol 15:41-45.
57. Green LS, D Jellinek, C Bell, LA Beebe, BD Feistner, SC Gill, FM Jucker and N Janjic. (1995). Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 2:683-695.
58. Ruckman J, LS Green, J Beeson, S Waugh, WL Gillette, DD Henninger, L Claesson-Welsh and N Janjic. (1998). 2-Fluoropyrimidine RNA-based aptamers to the 165-Amino acid form of vascular endothelial growth factor (VEGF165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon-7-encoded domain. J Biol Chem 273:20556-20567.
59. Shaw JP, K Kent, J Bird, J Fishback and B Froehler. (1991). Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res 19:747-750.
60. DiSalvo J, ML Bayne, G Conn, PW Kwok, PG Trivedi, DD Soderman, TM Palisi, KA Sullivan and KA Thomas. (1995). Purification and characterization of a naturally occurring vascular endothelial growth factor/placenta growth factor heterodimer. J Biol Chem 270:7717-7723.
61. Cao Y, H Chen, L Zhou, MK Chiang, B Anand-Apte, JA Weatherbee, Y Wang, F Fang, JG Flanagan and ML Tsang. (1996). Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 271:3154-3162.
62. Janjic N and L Gold. (1998). High-Affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF). Patent No. US 5811533 A.
63. Rohloff JC, AD Gelinas, TC Jarvis, UA Ochsner, DJ Schneider, L Gold and N Janjic. (2014). Nucleic acid li-gands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents. Mol Ther Nucleic Acids 3:e201.
64. Lee J-H, MD Canny, A De Erkenez, D Krilleke, YS Ng, DT Shima, A Pardi and F Jucker. (2005). A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A 102:18902-18907.
65. Lee J-H, F Jucker and A Pardi. (2008). Imino proton exchange rates imply an induced-fit binding mechanism for the VEGF165-Targeting aptamer, Macugen. FEBS Lett 582:1835-1839.
66. de Smidt PC, T Le Doan, S de Falco and TJC van Berkel. (1991). Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res 19:4695-4700.
67. Jäschke A, JP Fürste, E Nordhoff, F Hillenkamp, D Cech and VA Erdmann. (1994). Synthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates. Nucleic Acids Res 22:4810-4817.
68. Kawaguchi T, H Asakawa, Y Tashiro, K Juni and T Sueishi. (1995). Stability, specific binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5-Terminal with poly (ethylene glycol). Biol Pharm Bull 18:474-476.
69. Willis MC, B Collins, T Zhang, LS Green, DP Sebesta, C Bell, E Kellogg, SC Gill, A Magallanez, et al. (1998). Liposome-Anchored vascular endothelial growth factor aptamers. Bioconj Chem 9:573-582.
70. Macugen (pegaptanib sodium) Pharmacology Review. (2004). Retrieved July 20, 2015 from Drugs@FDA web site www.accessdata.fda.gov/drugsatfda-docs/nda/2004/21-756-Macugen-pharmr.pdf. 11/2004
71. Tucker CE, L-S Chen, MB Judkins, JA Farmer, SC Gill, A Magallanez, S Knauer, RA Bendele, PS Gill and N Janjic. (1999). Detection and plasma pharmacokinetics of an antivascular endothelial growth factor oligonucleotide-Aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 732:203-212.
72. Drolet DW, J Nelson, CE Tucker, PM Zack, K Nixon, R Bolin, MB Judkins, JA Farmer, JL Wolf, SC Gill and RA Bendele. (2000). Pharmacokinetics and safety of an antivascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17:1503-1510.
73. Eyetech Study Group. (2002). Preclinical and phase 1A evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22:143-152.
74. Bell C, E Lynam, DJ Landfair, N Janjic and ME Wiles. (1999). Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 35:533-542.
75. Ishida S, T Usui, K Yamashiro, Y Kaji, E Ahmed, KG Carrasquillo, S Amano, T Hida, Y Oguchi, et al. (2003). VEGF 164 is proinflammatory in the diabetic retina. Invest Opthalmol Vis Sci 44:2155.
76. Macugen: EPAR-Scientific Discussion. (2006). Retrieved July 20, 2015 from European Medicines Agency web site www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000620/WC500026218.pdf 2006
77. Foy JW, K Rittenhouse, M Modi and M Patel. (2007). Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit. J Ocul Pharmacol Ther 23:452-466.
78. Zhang F, MR Liu and HT Wan. (2014). Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biol Pharm Bull 37:335-339.
79. Eyetech Study Group. (2003). Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 110:979-986.
80. Gragoudas ES, AP Adamis, ET Cunningham, M Feinsod and DR Guyer. (2004). Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816.
81. Ng EWM, DT Shima, P Calias, ET Cunningham, DR Guyer and AP Adamis. (2006). Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123-132.
82. Brown DM, PK Kaiser, M Michels, G Soubrane, JS Heier, RY Kim, JP Sy, S Schneider and ANCHOR Study Group. (2006). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444.
83. Rosenfeld PJ, DM Brown, JS Heier, DS Boyer, PK Kaiser, CY Chung, RY Kim and MARINA Study Group. (2006). Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431.
84. Heier JS, DM Brown, V Chong, J-F Korobelnik, PK Kaiser, QD Nguyen, B Kirchhof, A Ho, Y Ogura, et al. (2012). Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537-2548.
85. CATT Research Group, DF Martin, MG Maguire, GS Ying, JE Grunwald, SL Fine and GJ Jaffe. (2011). Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897-1908.
86. Holash J, S Davis, N Papadopoulos, SD Croll, L Ho, M Russell, P Boland, R Leidich, D Hylton, et al. (2002). VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398.
87. Lowe J, J Araujo, J Yang, M Reich, A Oldendorp, V Shiu, V Quarmby, H Lowman, S Lien, et al. (2007). Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 85:425-430.
88. Dixon JA, SCN Oliver, JL Olson and N Mandava. (2009). VEGF trap-eye for the treatment of neovascular agerelated macular degeneration. Expert Opin Invest Drugs 18:1573-1580.
89. DAmore PA. (2007). Vascular endothelial cell growth factor-A. Am J Pathol 171:14-18.
90. Friberg TR and M Tolentino. (2010). Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: The LEVEL study. Br J Ophthalmol 94:1611-1617.
91. Ishibashi T, LEVEL-J Study Group. (2013). Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: An exploratory study in Japanese patients (LEVEL-J study). Jpn J Ophthalmol 57:417-423.
92. Inoue M, K Kadonosono, A Arakawa, S Yamane and T Ishibashi. (2015). Long-Term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol 59:173-178.
93. Agrawal S, M Joshi and JB Christoforidis. (2013). Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm 2013:943409.
94. Boyer DS, M Goldbaum, AM Leys and C Starita. (2014). Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study. Br J Ophthalmol 98:1543-1546.
95. Choi DY, MC Ortube, CA McCannel, D Sarraf, JP Hubschman, TA McCannel and MB Gorin. (2011). Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 31:1028-1035.
96. Steffensmeier AC, AE Azar, JJ Fuller, BA Muller and SR Russell. (2007). Vitreous injections of pegaptanib sodium triggering allergic reactions. Am J Ophthalmol 143:512-513.
97. Highlights of Prescribing Information LUCENTIS-(ranibizumab injection) Intravitreal Injection. (2015). Retrieved September 24, 2015 from Drugs@FDA web site www .accessdata.fda.gov/drugsatfda-docs/label/2015/125156s106 lbl.pdf 2/2015
98. Benjamin LE, I Hemo and E Keshet. (1998). A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591-1598.
99. Alon T, I Hemo, A Itin, J Peer, J Stone and E Keshet. (1995). Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024-1028.
100. Benjamin LE, D Golijanin, A Itin, D Pode and E Keshet. (1999). Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165.
101. Oefner C, A DArcy, FK Winkler, B Eggimann and M Hosang. (1992). Crystal structure of human plateletderived growth factor BB. EMBO J 11:3921-3926.
102. Claesson-Welsh L, A Eriksson, B Westermark and CH Heldin. (1989). cDNA cloning and expression of the human A-Type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-Type PDGF receptor. Proc Natl Acad Sci U S A 86:4917-4921.
103. Heldin CH. (1992). Structural and functional studies on platelet-derived growth factor. EMBO J 11:4251-4259.
104. Claesson-Welsh L. (1994). Platelet-derived growth factor receptor signals. J Biol Chem 269:32023-32026.
105. Bergsten E, M Uutela, X Li, K Pietras, A Ostman, CH Heldin, K Alitalo and U Eriksson. (2001). PDGF-D is a specific, protease-Activated ligand for the PDGF betareceptor. Nat Cell Biol 3:512-516.
106. Gilbertson DG, ME Duff, JW West, JD Kelly, PO Sheppard, PD Hofstrand, Z Gao, K Shoemaker, TR Bukowski, et al. (2001). Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem 276:27406-27414.
107. Reigstad LJ, JE Varhaug and JR Lillehaug. (2005). Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 272:5723-5741.
108. Ray S, C Gao, K Wyatt, RN Fariss, A Bundek, P Zelenka and G Wistow. (2004). Platelet-derived growth factor D, tissuespecific expression in the eye, and a key role in control of lens epithelial cell proliferation. J Biol Chem 280:8494-8502.
109. Mudhar HS, RA Pollock, C Wang, CD Stiles and WD Richardson. (1993). PDGF and its receptors in the developing rodent retina and optic nerve. Development 118:539-552.
110. Uemura A, M Ogawa, M Hirashima, T Fujiwara, S Koyama, H Takagi, Y Honda, SJ Wiegand, GD Yancopoulos, et al. (2002). Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 110:1619-1628.
111. Hermansson M, M Nister, C Betsholtz, CH Heldin, B Westermark and K Funa. (1988). Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci U S A 85:7748-7752.
112. Leveen P, M Pekny, S Gebre-Medhin, B Swolin, E Larsson and C Betsholtz. (1994). Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8:1875-1887.
113. Soriano P. (1994). Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 8:1888-1896.
114. Lindahl P. (1997). Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242-245.
115. Bjarnegard M, M Enge, J Norlin, S Gustafsdottir, S Fredriksson, A Abramsson, Takemoto, M, E Gustafsson R Fässler, et al. (2004). Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities. Development 131:1847-1857.
116. Nomura M, S Yamagishi, S Harada, Y Hayashi, T Yamashima, J Yamashita and H Yamamoto. (1995). Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 270:28316-28324.
117. Takagi H, GL King and LP Aiello. (1996). Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 45: 1016-1023.
118. Yamagishi S, H Yonekura, Y Yamamoto, H Fujimori, S Sakurai, N Tanaka and H Yamamoto. (1999). Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 79:501-509.
119. Darland DC, LJ Massingham, SR Smith, E Piek, M Saint-Geniez and PA DAmore. (2003). Pericyte production of cell-Associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 264:275-288.
120. Erber R, A Thurnher, AD Katsen, G Groth, H Kerger, HP Hammes, MD Menger, A Ullrich and P Vajkoczy. (2004). Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338-340.
121. Kim I, HG Kim, JN So, JH Kim, HJ Kwak and GY Koh. (2000). Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Circ Res 86:24-29.
122. Hawighorst T, M Skobe, M Streit, Y-K Hong, P Velasco, LF Brown, L Riccardi, B Lange-Asschenfeldt and M Detmar. (2002). Activation of the Tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 160:1381-1392.
123. White RR, S Shan, CP Rusconi, GShetty, MW Dewhirst, CD Kontos and BA Sullenger. (2003). Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. ProcNatlAcad SciUSA100:5028-5033.
124. Bergers G, S Song, N Meyer-Morse, E Bergsland and D Hanahan. (2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295.
125. Pietras K and D Hanahan. (2005). A multitargeted, metronomic, and maximum-Tolerated dose chemo-switch regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23:939-952.
126. Shen J, MD Vil, H Zhang, JR Tonra, LL Rong, C Damoci, M Prewett, DS Deevi, J Kearney, et al. (2007). An antibody directed against PDGF receptor b enhances the antitumor and the anti-Angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun 357:1142-1147.
127. Mabry R, DG Gilbertson, A Frank, T Vu, D Ardourel, C Ostrander, BL Stevens, SH Julien, S Franke, et al. (2010).A dual-Targeting PDGFRb/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-Angiogenic activity in vitro and in vivo. mAbs 2:20-34.
128. Jo N, C Mailhos, M Ju, E Cheung, J Bradley, K Nishijima, GS Robinson, AP Adamis and DT Shima. (2006). Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168:2036-2053.
129. Green LS, D Jellinek, R Jenison, A Ostman, CH Heldin and N Janjic. (1996). Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35:14413-14424.
130. Floege J, T Ostendorf, U Janssen, M Burg, HH Radeke, C Vargeese, SC Gill, LS Green and N Janjic. (1999). Novel approach to specific growth factor inhibition in vivo. AmJ Pathol 154:169-179.
131. Guschlbauer W and K Jankowski. (1980). Nucleoside conformation is determined by the electronegativity of the sugar substituent. Nucleic Acids Res 8:1421-1433.
132. Leppänen O, N Janjic, MA Carlsson, K Pietras, M Levin, C Vargeese, LS Green, D Bergqvist, A Ostman, et al. (2000). Intimal hyperplasia recurs after removal of PDGFAB and-BB inhibition in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol 20:e89-e95.
133. Ostendorf T, U Kunter, HJ Gröne, F Bahlmann, H Kawachi, F Shimizu, KM Koch, N Janjic and J Floege. (2001). Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 12:909-918.
134. Pietras K, A Ostman, M Sjöquist, E Buchdunger, RK Reed, CH Heldin and K Rubin. (2001). Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929-2934.
135. Jain RK. (1987). Transport of molecules in the tumor interstitium: A review. Cancer Res 47:3039-3051.
136. Jain RK. (1996). Delivery of molecular medicine to solid tumors. Science 271:1079-1080.
137. Pietras K, K Rubin, T Sjöblom, E Buchdunger, M Sjö-quist, CH Heldin and A Ostman. (2002). Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484.
138. Balasubramaniam V, TD Le Cras, DD Ivy, TR Grover, JP Kinsella and SH Abman. (2003). Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284:L826-L833.
139. Akiyama H, S Kachi, E RL Silva, N Umeda, SF Hackett, D McCauley, T McCauley, A Zoltoski, DM Epstein, et al. (2006). Intraocular injection of an aptamer that binds PDGFB: A potential treatment for proliferative retinopathies. J Cell Physiol 207:407-412.
140. Seo MS, N Okamoto, MA Vinores, SA Vinores, SF Hackett, H Yamada, E Yamada, NL Derevjanik, W LaRochelle, et al. (2000). Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol 157:995-1005.
141. Boyer DS and Ophthotech Anti-PDGF in AMD Study Group. (2009). Combined inhibition of platelet derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD)-results of a phase 1 study. Invest Opthalmol Vis Sci 50:Abstract No. 1260.
142. Ophthotech Corporation. (2013). A phase 3 safety and efficacy study of fovista-(E10030) intravitreous administration in combination with either vastin-or Eylea-compared to Avastin-or Eyelea-monotherapy. Retrieved September 24, 2015 from ClinicalTrials.gov web site https://clinicaltrials. gov/ct2/show/NCT01944839?term=fovista&rank=3
143. Dunkelberger JR and W-C Song. (2009). Complement and its role in innate and adaptive immune responses. Cell Res 20:34-50.
144. Sarma JV and PA Ward. (2010). The complement system. Cell Tissue Res 343:227-235.
145. Biesecker G, L Dihel, K Enney and RA Bendele. (1999). Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 42:219-230.
146. Ricklin D and JD Lambris. (2013). Complement in immune and inflammatory disorders: Therapeutic interventions. J Immunol 190:3839-3847.
147. Ricklin D and JD Lambris. (2007). Complement-Targeted therapeutics. Nat Biotechnol 25:1265-1275.
148. Rother RP, SA Rollins, CF Mojcik, RA Brodsky and L Bell. (2007). Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256-1264.
149. Hageman GS, PJ Luthert, NH Victor Chong, LV Johnson, DH Anderson and RF Mullins. (2001). An integrated hypothesis that considers drusen as biomarkers of immunemediated processes at the RPE-Bruchs membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 20:705-732.
150. Johnson LV, WP Leitner, MK Staples and DH Anderson. (2001). Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res 73:887-896.
151. Nozaki M, BJ Raisler, E Sakurai, JV Sarma, SR Barnum, JD Lambris, Y Chen, K Zhang, BK Ambati, et al. (2006). Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad SciUSA103:2328-2333.
152. Bradley DT, PF Zipfel and AE Hughes. (2011). Complement in age-related macular degeneration: A focus on function. Eye 25:683-693.
153. Hecker LA, AO Edwards, E Ryu, N Tosakulwong, KH Baratz, WL Brown, P Charbel Issa, HP Scholl, B Pollok-Kopp, et al. (2010). Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet 19:209-215.
154. Reynolds R, ME Hartnett, JP Atkinson, PC Giclas, B Rosner and JM Seddon. (2009). Plasma complement components and activation fragments: Associations with age-related macular degeneration genotypes and phenotypes. Invest Opthalmol Vis Sci 50:5818-5827.
155. Scholl HPN, PC Issa, M Walier, S Janzer, B Pollok-Kopp, F Börncke, LG Fritsche, NV Chong, R Fimmers, et al. (2008). Systemic complement activation in age-related macular degeneration. PLoS One 3:e2593.
156. Silva AS, AG Teixeira, L Bavia, F Lin, R Velletri, R Belfort Jr., and L Isaac. (2012). Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of Complement Factor H Tyr(4)(0)(2)His polymorphism. Mol Vis 18:2288-2299.
157. Stanton CM, JRW Yates, AI den Hollander, JM Seddon, A Swaroop, D Stambolian, S Fauser, C Hoyng, Y Yu, et al. (2011). Complement factor D in age-related macular degeneration. Invest Opthalmol Vis Sci 52:8828.
158. Cascella R, M Ragazzo, C Strafella, F Missiroli, P Borgiani, F Angelucci, LT Marsella, A Cusumano, G Novelli, et al. (2014). Age-related macular degeneration: insights into inflammatory genes. J Ophthalmol 2014:1-9.
159. Bora PS, JH Sohn, JMC Cruz, P Jha, H Nishihori, Y Wang, S Kaliappan, HJ Kaplan and NS Bora. (2004). Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol 174:491-497.
160. Brockmann C, T Brockmann, S Dege, C Busch, N Kociok, A Vater, S Klussmann, O Strauß and AM Joussen. (2015). Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice. Graefes Arch Clin Exp Ophthalmol 253:1695-1704.
161. Chi Z-L, T Yoshida, JD Lambris and T Iwata. (2010). Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv Exp Med Biol 703:127-135.
162. Ambati J, JP Atkinson andBDGelfand. (2013). Immunology of age-related macular degeneration. Nat Rev Immunol 13:438-451.
163. Jensen KB, L Green, S MacDougal-Waugh and C Tuerk. (1994). Characterization of an in vitro-selected RNA ligand to the HIV-1 rev protein. J Mol Biol 235:237-247.
164. Epstein D and JC Kurz. Inventors. Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders (see paragraph [00120] in PCT application No. PCT/US2007/06020, filed on March 8, 2007 and published September 13, 2007. Retrieved July 20, 2015. https://patents cope.wipo.int/search/en/detail.jsf?docId =WO2007103549)
165. Monés J. (2010). Complement factor 5 inhibition in agerelated macular degeneration. Retina Today 5:52-55.
166. Vitravene Study Group. (2002). A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 133:467-474.
167. Burnett JC and JJ Rossi. (2012). RNA-based therapeutics: current progress and future prospects. Chem Biol 19:60-71.
168. van Rooij E, AL Purcell and AA Levin. (2012). Developing microRNA therapeutics. Circ Res 110:496-507.
169. Urtti A. (2006). Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58: 1131-1135.
170. Gaudana R, HK Ananthula, A Parenky and AK Mitra. (2010). Ocular drug delivery. AAPS J 12:348-360.
171. Jackson TL, RJAntcliff, JHillenkamp and JMarshall. (2003). Human retinal molecular weight exclusion limit and estimate of species variation. Invest Opthalmol Vis Sci 44:2141.
172. Shahar J, RL Avery, GAD Heilweil, A Barak, E Zemel, GP Lewis, PT Johnson, SK Fisher, I Perlman, et al. (2006). Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (avastin). Retina 26:262-269.
173. De Fougerolles AR and JM Maraganore. (2008). Discovery and development of RNAi therapeutics. In: Crooke S, ed. Antisense Drug Technology: Principles, Strategies and Applications. CRC Press, Boca Raton, FL, pp 466-481.
174. Falavarjani KG and QD Nguyen. (2013). Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature. Eye (Lond) 27:787-794.
175. Regillo CD, DM Brown, P Abraham, H Yue, T Ianchulev, S Schneider and N Shams. (2008). Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 145:239-248.e235.
176. Wu F and T Jin. (2008). Polymer-based sustained-release dosage forms for protein drugs, challenges, and recent advances. AAPS PharmSciTech 9:1218-1229.
177. Ratanji KD, JP Derrick, RJ Dearman and I Kimber. (2014). Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol 11:99-109.
178. Kessler M. (2006). Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 21:v9-v12.
179. Vaught JD, C Bock, J Carter, T Fitzwater, M Otis, D Schneider, J Rolando, S Waugh, SK Wilcox, et al. (2010). Expanding the chemistry of DNA for in vitro selection. J Am Chem Soc 132:4141-4151.
180. Gold L, D Ayers, J Bertino, C Bock, A Bock, EN Brody, J Carter, AB Dalby, BE Eaton, et al. (2010). Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5:e15004.
181. Davies DR, AD Gelinas, C Zhang, JC Rohloff, JD Carter, D OConnell, SM Waugh, SK Wolk, WS Mayfield, et al. (2012). Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc Natl Acad Sci U S A 109:19971-19976.
182. Dassie JP and PH Giangrande. (2013). Current progress on aptamer-Targeted oligonucleotide therapeutics. Ther Deliv 4:1527-1546.
183. Zhou J and JJ Rossi. (2014). Cell-Type-specific, aptamerfunctionalized agents for targeted disease therapy. Mol Ther Nucleic Acids 3:e169.
184. Bouchard PR, RM Hutabarat and KM Thompson. (2010). Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 50:237-257.
185. Keefe AD, S Pai and A Ellington. (2010). Aptamers as therapeutics. Nat Rev Drug Discov 9:537-550.
186. Esposito CL, S Catuogno, V de Franciscis and L Cerchia. (2011). New insight into clinical development of nucleic acid aptamers. Discov Med 11:487-496.
187. Richardson FC, BC Tennant, DJMeyer, KA Richardson, PC Mann, GR McGinty, JL Wolf, PM Zack and RA Bendele. (1999). An evaluation of the toxicities of 2-fluorouridine and 2-fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax). Toxicol Pathol 27:607-617.
188. Richardson FC, C Zhang, SR Lehrman, H Koc, JA Swenberg, KA Richardson and RA Bendele. (2002). Quantification of 2-fluoro-2deoxyuridine and 2-fluoro-2deoxycytidine in DNA and RNA isolated from rats and woodchucks using LC/MS/MS. Chem Res Toxicol 15:922-926.
189. Eming SA and T Krieg. (2006). Molecular mechanisms of VEGF-A action during tissue repair. J Invest Dermatol Symp Proc 11:79-86.